original ) (raw )The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies
Fabiana Tatangelo
Cancer Biology & Therapy, 2013
View PDFchevron_right
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
Roscoe Morton
Journal of Clinical Oncology, 2009
View PDFchevron_right
Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer
Michelle Benchimol
Annals of Oncology, 2008
View PDFchevron_right
KRAS Mutation Testing in the Treatment of Metastatic Colorectal Cancer with Anti-EGFR Therapies
Denis Soulières
Current Oncology, 2010
View PDFchevron_right
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy
Sandra Misale , Pierre Laurent-puig
International Journal of Cancer, 2013
View PDFchevron_right
Molecular predictors of response to EGFR antibodies in colorectal cancer
Pierre Laurent-puig
Current Colorectal Cancer Reports, 2009
View PDFchevron_right
Understanding the Predictive Role of K-ras for Epidermal Growth Factor Receptor–Targeted Therapies in Colorectal Cancer
Francisco Javier Peña Ramos
Clinical Colorectal Cancer, 2008
View PDFchevron_right
Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance
Michele Caraglia
Expert Opinion on Biological Therapy, 2013
View PDFchevron_right
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Michel Ducreux
Cancer Research, 2006
View PDFchevron_right
The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer
Niels Pallisgaard , Anders Jakobsen
Annals of Oncology, 2009
View PDFchevron_right
Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer
Pierre Laurent-puig
International Journal of Cancer, 2010
View PDFchevron_right
Effect of KRAS mutational status in advanced colorectal cancer on the outcomes of anti-epidermal growth factor receptor monoclonal antibody therapy: a systematic review and meta-analysis
Shelley Salpeter
Clinical colorectal cancer, 2011
View PDFchevron_right
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
Pamela McAllister
Journal of Clinical Oncology, 2009
View PDFchevron_right
The Long and Winding Road to Useful Predictive Factors for Anti-EGFR Therapy in Metastatic Colorectal Carcinoma: The KRAS/BRAF Pathway
Antonio Russo , Viviana Bazan , Nicola Silvestris
Oncology, 2009
View PDFchevron_right
EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy
Erzsebet Raso
Cancers
View PDFchevron_right
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
Giovanna Marrapese
The Lancet Oncology, 2005
View PDFchevron_right
Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy
Ying Ma
View PDFchevron_right
Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation
Mario Scartozzi
Critical Reviews in Oncology/Hematology, 2013
View PDFchevron_right
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
marcello gambacorta
Nature, 2012
View PDFchevron_right
Explaining the Unexplainable: EGFR Antibodies in Colorectal Cancer
Axel Grothey
Journal of Clinical Oncology, 2012
View PDFchevron_right
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy
Daniel Bazan
Cancer Treatment Reviews, 2010
View PDFchevron_right
Molecular predictive factors of response to anti-EGFR antibodies in colorectal cancer patients
Giuseppe Tonini
European Journal of Cancer Supplements, 2008
View PDFchevron_right
EGFR Protein Expression of KRAS Wild-Type Colorectal Cancer: Predictive Value of the Sidedness for Efficacy of Anti-EGFR Therapy
Andrea Uhlyarik
Pathology & Oncology Research, 2019
View PDFchevron_right
Pyrosequencing evaluation of low-frequency KRAS mutant alleles for EGF receptor therapy selection in metastatic colorectal carcinoma
Michele Aieta , Matteo Landriscina
Future Oncology, 2014
View PDFchevron_right
Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with KRAS p.G13D Mutation
Yukinari Kato
International Journal of Molecular Sciences
View PDFchevron_right
Anti-Epidermal Growth Factor Receptor Monotherapy in the Treatment of Metastatic Colorectal Cancer: Where Are We Today?
Timothy Price
The Oncologist, 2009
View PDFchevron_right
Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer
S. Arena
Targeted Oncology, 2010
View PDFchevron_right